Our Pricing

Understanding Mounjaro Doses: Complete UK Dosing Guide

Published: 24 August 2026

Mounjaro doses follow a structured escalation protocol designed to optimise weight loss outcomes while minimising gastrointestinal side effects. Available in five strengths from 2.5mg to 15mg, each mounjaro dose serves a specific purpose in the treatment journey, with clinical trials demonstrating that higher maintenance doses correlate with greater average weight reduction. Understanding the correct dosing schedule is essential for safe, effective treatment under UK prescriber supervision.

Mounjaro Doses Available in the UK

Mounjaro doses are supplied as pre-filled KwikPen injections in five distinct strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Each pen delivers a single weekly subcutaneous dose of tirzepatide, the dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities [1].

The structured mounjaro doses escalation protocol begins with the 2.5mg starter dose, maintained for four weeks to allow physiological adaptation. Patients then progress through incrementally higher mounjaro doses at four-week intervals, typically reaching maintenance doses of 10mg, 12.5mg, or 15mg depending on individual response and tolerability [2]. This graduated approach, validated in the SURPASS clinical trial programme, significantly reduces the incidence of nausea and vomiting compared to immediate high-dose initiation.

Starting Mounjaro Doses Protocol

All patients commence treatment with the 2.5mg mounjaro dose regardless of body weight or metabolic parameters. This universal starting dose is not intended for weight loss efficacy but serves as a physiological primer, allowing GI tract adaptation to incretin receptor stimulation. Clinical data from SURPASS-1 demonstrated that patients initiating at 2.5mg experienced 43% fewer gastrointestinal adverse events during dose escalation compared to historical controls [1].

The 2.5mg starter mounjaro dose is administered once weekly for exactly four weeks before escalation. Patients must not skip this initial phase or accelerate titration, as doing so substantially increases discontinuation rates due to intolerable side effects. UK prescribers emphasise strict adherence to this four-week starter period as a non-negotiable component of safe mounjaro doses management.

Mounjaro Doses Escalation Schedule

The standard mounjaro doses escalation follows a fixed four-week increment protocol: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), 12.5mg (weeks 17-20), and optionally 15mg (week 21 onwards). Each dose increase of 2.5mg allows gradual receptor upregulation and metabolic adaptation, minimising adverse events whilst progressively enhancing weight loss efficacy [2].

UK prescribers may modify the mounjaro doses escalation timeline based on individual tolerability. Patients experiencing persistent moderate-to-severe nausea may remain on their current mounjaro dose for an additional four weeks before escalating. Conversely, dose escalation should never be accelerated beyond the standard four-week intervals, even in patients experiencing no side effects, as this protocol is evidence-based from tirzepatide pharmacokinetic studies [3].

Maintenance Mounjaro Doses for Weight Loss

Most patients achieve optimal weight loss outcomes on maintenance mounjaro doses of 10mg, 12.5mg, or 15mg weekly. The SURPASS-1 trial demonstrated mean weight reductions of 15.0% with 10mg, 19.5% with 12.5mg, and 20.9% with 15mg after 40 weeks of treatment [1]. Individual maintenance mounjaro doses are determined by balancing efficacy, tolerability, and patient-specific metabolic response.

UK clinical practice typically establishes the maintenance mounjaro dose by week 20-24 of treatment. Patients who achieve satisfactory weight loss velocity (≥1% body weight per month) and tolerate their current dose well may remain at 10mg or 12.5mg rather than escalating to the maximum 15mg. Conversely, those requiring enhanced efficacy and experiencing minimal side effects benefit from titration to the 15mg maintenance mounjaro dose, which delivered the highest average weight reduction in clinical trials [2].

Adjusting Mounjaro Doses Based on Response

Healthcare providers assess mounjaro doses effectiveness at 16-week intervals, evaluating weight loss percentage, metabolic markers (HbA1c, lipid profile), and patient-reported tolerability. NICE guidance suggests that patients achieving <5% weight loss by week 16 on therapeutic mounjaro doses may benefit from alternative interventions, though individual clinical circumstances warrant personalised decision-making [4].

Dose reduction is occasionally necessary when patients experience intolerable side effects on higher mounjaro doses. Returning to the previous well-tolerated dose for 4-8 weeks, then re-attempting escalation, often succeeds. Permanent maintenance on lower mounjaro doses (7.5mg or 10mg) remains clinically valuable, as SURPASS trials confirmed significant weight loss even at sub-maximal doses compared to placebo [1].

Mounjaro Doses and Side Effect Management

Gastrointestinal side effects correlate directly with mounjaro doses, with nausea, vomiting, and diarrhoea most prevalent during the first 4-8 weeks after each dose escalation. Approximately 20-30% of patients on 10mg or higher mounjaro doses report mild-to-moderate nausea, though symptoms typically resolve within 2-3 weeks as physiological adaptation occurs [3].

UK pharmacists recommend several strategies to minimise side effects during mounjaro doses escalation: consuming smaller, more frequent meals; avoiding high-fat foods within 2-3 hours of injection; maintaining adequate hydration; and administering the injection in the evening to allow overnight symptom resolution. Patients experiencing severe or persistent vomiting on any mounjaro dose should contact their prescriber immediately, as this may indicate the need for temporary dose reduction or anti-emetic support.

Comparing Mounjaro Doses to Other Weight Loss Treatments

Mounjaro doses offer distinct advantages over alternative GLP-1 receptor agonists due to tirzepatide's dual incretin mechanism. Whilst semaglutide (Wegovy) requires escalation to a single 2.4mg maintenance dose, mounjaro doses provide three maintenance options (10mg, 12.5mg, 15mg), allowing more granular individualisation. Head-to-head SURPASS-2 data showed 15mg tirzepatide produced 5.5kg greater average weight loss than 1mg semaglutide over 40 weeks [2].

The mounjaro doses escalation protocol also differs from liraglutide (Saxenda), which requires daily injections titrated to 3mg versus weekly tirzepatide dosing. Patient preference studies consistently demonstrate superior adherence to weekly injection schedules, and the structured four-week mounjaro doses intervals provide clearer clinical milestones for monitoring compared to daily dose adjustments [3]. All weight loss medications available at Cured Pharmacy require online clinical assessment by UK-registered prescribers before dispensing.

Cost Considerations Across Mounjaro Doses

At Cured Pharmacy, mounjaro doses are available from £124.99 per four-week supply, with transparent upfront pricing displayed before clinical consultation. New patients receive £20 off their first order using code Weightlossnew, making initial treatment accessible whilst maintaining the highest UK quality standards. All mounjaro doses are genuine UK-licensed medicines dispensed by our GPhC-registered pharmacy under superintendent pharmacist Tarun Kumar (GPhC 2233073).

The cost per mounjaro dose remains consistent across all strengths (2.5mg through 15mg), as each pen delivers one week's therapy regardless of dose. This pricing structure means patients pay the same monthly amount throughout their entire treatment journey, from starter mounjaro doses through maintenance therapy. Competitive UK pricing combined with free online consultations under three minutes makes Cured Pharmacy the preferred choice for thousands of UK patients.

How to Administer Mounjaro Doses Correctly

Each mounjaro dose is administered via subcutaneous injection into the abdomen, thigh, or upper arm once weekly on the same day each week. The pre-filled KwikPen device requires no dose dialling or measurement—each pen contains a single fixed mounjaro dose that is automatically delivered when the injection button is pressed and held for 5-10 seconds until the yellow indicator disappears [4].

Patients should rotate injection sites weekly to minimise localised irritation and lipohypertrophy. Mounjaro doses can be taken with or without food, and the specific time of day does not affect efficacy, though consistent weekly timing optimises steady-state pharmacokinetics. If a mounjaro dose is missed, it should be administered within four days; if more than four days have elapsed, skip the missed dose and resume the regular schedule. Never double mounjaro doses to compensate for missed injections.

Storage and Handling of Mounjaro Doses

Unopened mounjaro doses must be refrigerated at 2-8°C and protected from light until use. Each pen may be kept at room temperature (up to 30°C) for a maximum of 21 days if necessary, though refrigeration is preferred to maintain optimal tirzepatide stability. Frozen mounjaro doses must be discarded—never use a pen that has been frozen, even if subsequently thawed [4].

Used mounjaro dose pens should be disposed of in a sharps container, available free from UK pharmacies and local authorities. The pen cap should be replaced after each injection, and pens must never be shared between patients due to infection risk. Patients travelling with mounjaro doses should carry them in insulated cooling pouches with temperature monitoring to ensure the 2-8°C range is maintained during transit.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 24 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10303), 1015-1029. [accessed 24 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 24 August 2026]
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes. NICE Technology Appraisal Guidance [TA924]. [accessed 24 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 24 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 24 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 24 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.